Ann: Cellmid Share Purchase Plan, page-12

Shareholders will get their return on Advangen alone. There are criticisms of promises not being met yet I can't recall any. Cellmid's a biotech with long lead time development programs. Advangen is the entity expected to be the first to profitability. They estimates $100M revenue in 7 years, plenty of time yet.
We now have a promise of profitability by month in 2019. That's only 5 months away. If they are making statements like that now, they have that locked away.

Dennis Eck and the Chairman seem to be pretty buddy buddy judging by their Instagram pictures. Is it possible that Evolis won't be part of the Ulta suite of products before the end of the year?

DYOR